Background & relevance
Men with PSA-detected clinically localised PCa have excellent 10-year survival rates irrespective of the treatment (ProtecT trial). Is treatment choice here just a matter of patient preference?
Men with PSA-detected clinically localised PCa have excellent 10-year survival rates irrespective of the treatment (ProtecT trial). Is treatment choice here just a matter of patient preference?